Loading clinical trials...
Loading clinical trials...
Randomized Phase III Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients
Conditions
Interventions
Trabectedin
Pegylated Liposomal Doxorubicin
+4 more
Locations
1
Italy
Domenica Lorusso
Rome, Italy
Start Date
April 11, 2016
Primary Completion Date
December 20, 2018
Completion Date
December 20, 2018
Last Updated
August 25, 2021
NCT07213804
NCT06051695
NCT06885697
NCT07035587
NCT01789229
NCT02869568
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions